Skeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study

被引:1
|
作者
Lee, Ji Yun [1 ]
Lee, Ju-Hyun [1 ]
Seo, Jeongmin [1 ]
Kang, Minsu [1 ]
Jung, Eun Hee [1 ]
Kim, Sang-A [1 ]
Suh, Koung Jin [1 ]
Kim, Ji-Won [1 ]
Kim, Se Hyun [1 ]
Lee, Jeong-Ok [1 ]
Kim, Jin Won [1 ]
Kim, Yu Jung [1 ]
Lee, Keun-Wook [1 ]
Kim, Jee Hyun [1 ]
Lee, Jong Seok [1 ]
Bang, Soo-Mee [1 ]
机构
[1] Seoul Natl Univ, Seoul Natl Univ Bundang Hosp, Coll Med, Dept Internal Med, Gumi Ro 173 Beon Gil, Seongnam 13620, South Korea
关键词
Multiple Myeloma; Skeletal-Related Events; Korean; Incidence; Risk Factors; BONE; HEALTH; COMPLICATIONS; SURVIVAL; DISEASE;
D O I
10.3346/jkms.2024.39.e175
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Multiple myeloma (MM) patients are at risk of skeletal-related events (SREs) like spinal cord compression, pathologic fractures, bone surgery, and radiation to bone. Realworld data regarding SREs in MM are limited. Methods: We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service (HIRA) database from 2007 to 2018. Results: Over a 12-year study period, we identified 6,717 patients who developed symptomatic MM. After a median follow-up of 35.1 months (interquartile range [IQR], 20.8-58.2 months), 43.6% of these patients experienced SREs, and 39.6% had four or more SREs. One in five patients (20.0%) experienced pathologic fractures within the first year of follow-up. The median time to first SRE was 9.6 months (IQR, 1.2-25.8 months), with 3.0 months in the group with prior SREs and 19.8 months in the group without prior SREs. During follow-up, 78.5% of patients received bisphosphonates. Multiple logistic regression analysis revealed several factors associated with an increased risk of SREs, including being female (odds ratio [OR], 1.44), aged 50 or older (OR, 1.87), having cerebrovascular disease (OR, 1.34), undergoing first-line chemotherapy regimens not containing bortezomib or lenalidomide (OR, 1.49), and being in the group with prior SREs and bisphosphonate use (OR, 5.63), compared to the group without prior SREs and without bisphosphonate use. Conclusion: This population-based study is the first to report the incidence and risk factors of SREs in Korean MM patients, which can be used to assess their bone health.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [21] Factors associated with skeletal-related events in patients with bone metastatic melanoma: A retrospective study of 481 patients
    Shimizu, Michelle R.
    de Groot, Tom M.
    Twining, Peter K.
    Kobes, Tim
    Ferrone, Marco
    Raskin, Kevin
    Jutte, Paul C.
    Cohen, Sonia
    Lozano-Calderon, Santiago
    Groot, Olivier Q.
    Schwab, Joseph H.
    JOURNAL OF SURGICAL ONCOLOGY, 2024, 130 (02) : 310 - 321
  • [22] Natural history of skeletal-related events in patients with multiple myeloma: Exploratory analysis based on prior history of skeletal complications.
    Hussein, MA
    Kaminski, M
    Rosen, L
    Gordon, D
    Zheng, M
    BLOOD, 2004, 104 (11) : 314B - 314B
  • [23] Upregullation of TRAIL in Myeloma Cells Correlates with Skeletal-Related Events
    Kawano, Yawara
    Ueno, Shikiko
    Okuno, Yutaka
    Kikukawa, Yoshitaka
    Mitsuya, Hiroaki
    Hata, Hiroyuki
    BLOOD, 2009, 114 (22) : 1111 - 1111
  • [24] Assessment of Bone Health Education in US Multiple Myeloma and Solid Tumor Patients at Risk for Skeletal-Related Events
    Flora, Darcy R.
    Carlson, Katherine B.
    Fuehrer, David C.
    Cadieux, Benoit
    Boike, Guy
    Schenfeld, Jennifer
    Lowe, Kimberly A.
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 3529 - 3537
  • [25] Multiple skeletal-related events in a patient with breast cancer
    Vicent C, Herrero
    Pascual Pla, F. J.
    Samper Hiraldo, J. M.
    Gregori J, Gavila
    REVISTA DE OSTEOPOROSIS Y METABOLISMO MINERAL, 2013, 5 (04) : 147 - 149
  • [26] Pamidronate for the prevention of skeletal-related events in multiple myeloma - What does the public think it is worth?
    Dranitsaris, G
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 1999, 15 (01) : 108 - 122
  • [27] Healthcare resource utilisation associated with skeletal-related events in European patients with multiple myeloma: Results from a prospective, multinational, observational study
    Ashcroft, John
    Duran, Ignacio
    Hoefeler, Herbert
    Lorusso, Vito
    Lueftner, Diana
    Campioni, Marco
    Intorcia, Michele
    Bahl, Amit
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (05) : 479 - 487
  • [28] The Role of Denosumab for Prevention of Skeletal-Related Complications in Multiple Myeloma
    Hageman, Kelly
    Patel, Kiki Chandni
    Mace, Kimberly
    Cooper, Maryann R.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (7-8) : 1069 - 1074
  • [29] Utilization of agents to prevent skeletal-related events among patients with multiple myeloma: analysis of real-world data
    Yi Qian
    Debajyoti Bhowmik
    Nandita Kachru
    Rohini K Hernandez
    Paul Cheng
    Alexander Liede
    Supportive Care in Cancer, 2018, 26 : 807 - 812
  • [30] Skeletal-Related Events In Patients With Multiple Myeloma In The Era Of Novel Agents: Low Incidence Of Pathological Fractures After Treatment
    Terpos, Evangelos
    Kanellias, Nikolaos
    Moulopoulos, Lia A.
    Christoulas, Dimitrios
    Koureas, Andreas
    Bagratuni, Tina
    Koutoulidis, Vasilios
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    BLOOD, 2013, 122 (21)